eCourse
The New Section 102
Contains material from Mar 2017
The New Section 102
3.8 out of 5 stars
What was the overall quality of the course (presentation, materials, and technical delivery)?
Rate the overall teaching effectiveness and presentation skills of faculty for the course.
How would you rate the value of the materials provided as part of the course?
Presentation was a little too speculative.
Technical Questions?
512.475.6700
service@utcle.org
Explore the new Section 102, while focusing on the two areas of uncertainty within the new Section: does prior art need to be “available to the public” (see Helsinn Healthcare v. Teva Pharmaceuticals, on appeal to the Federal Circuit); and whether the one-year grace period under the new section is as robust as the one-year grace period under the previous section (or whether it is too soon to tell)?
Includes: Audio Slides
Preview mode.
You must be signed in, have purchased this eCourse,
and the eCourse must be active
to have full access.
Preview Sessions
Show session details
1.
The New Section 102 (Mar 2017)
Robert Bahr, Dale S. Lazar
1.00
0.00
0.00
Preview Materials
Download session materials for offline use
Session 1
—61 mins
The New Section 102 (Mar 2017)
Explore the new Section 102, while focusing on the two areas of uncertainty within the new Section: does prior art need to be “available to the public” (see Helsinn Healthcare v. Teva Pharmaceuticals, on appeal to the Federal Circuit); and whether the one-year grace period under the new section is as robust as the one-year grace period under the previous section (or whether it is too soon to tell)?
Originally presented: Mar 2017 Advanced Patent Law Institute
Robert Bahr,
U.S. Patent and Trademark Office - Alexandria, VA
Dale S. Lazar,
DLA Piper LLP US - Reston, VA